Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pharma Outsourcing
A look at three pharmaceutical outsourcing relationships shows that change is a constant in the biotech industry
by Michael McCoy
April 4, 2005
| A version of this story appeared in
Volume 83, Issue 14
CRITICAL LINK
[+]Enlarge
Credit: RHODIA PHOTO
Assistance from contract manufacturing operations, such as this one operated by Rhodia in Annan, Scotland, is crucial to small biotechnology firms.
Credit: RHODIA PHOTO
Assistance from contract manufacturing operations, such as this one operated by Rhodia in Annan, Scotland, is crucial to small biotechnology firms.
The biotechnology industry is a place of constant flux. Companies are formed, disbanded, and acquired. People move from firm to firm, job to job, gaining experience and contacts along the way.
It can be a difficult industry to serve, especially if the service being provided is one as critical as contract development or chemical manufacturing. Managers and corporate directions may change, but the biotech industry's demand for high-quality chemistry services remains the same.
In the pages to follow, C&EN presents three case studies of the relationship between a biopharmaceutical company and a pharmaceutical chemistry provider. Belying the biotech industry's discovery-oriented image, none of the three biotech firms pro-
filed developed its own drug. Rather, the compounds were licensed or acquired from other firms or institutions.
Uncertainty is created when a drug in development changes hands, but as these stories show, the successful service provider must be able to weather change and even use change to its advantage.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter